Intra-Cellular Therapies

Executive Summary

Intra-Cellular Therapies, now a part of Johnson & Johnson, is a biopharmaceutical company leveraging Nobel Prize-winning research on intracellular signaling to develop innovative small-molecule treatments for neuropsychiatric and neurologic disorders. Its lead product, Caplyta (lumateperone), is approved for schizophrenia and bipolar depression, offering a differentiated safety and efficacy profile. The company's pipeline includes next-generation candidates targeting Alzheimer's disease agitation, major depressive disorder, and other CNS conditions. With J&J's global commercial infrastructure, Intra-Cellular is well-positioned to maximize Caplyta's market potential and advance its pipeline through late-stage development. The integration is expected to accelerate clinical timelines and expand access to patients worldwide.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 readout for ITI-1284 in Alzheimer's disease agitation70% success
• H1 2027Supplemental NDA submission for Caplyta in major depressive disorder60% success
• Q3 2026Integration synergies and commercial expansion updates from J&J90% success